NHS
![Keytruda, NHS, NICE, Microsatellite instability, Mismatch repair deficient (dMMR) mutations](https://pharmtales.com/wp-content/uploads/2023/08/Keytruda-Gets-Green-Light-from-NHS-for-New-Cancer-‘Basket.jpg)
Keytruda Gets Green Light from NHS for New Cancer ‘Basket’
Anika Sharma
MSD’s Keytruda (pembrolizumab) has secured a significant recommendation from the UK’s National Institute for Health and Care Excellence (NICE), signaling ...
![NHS may increase the cost of new antibiotic subscriptions](https://pharmtales.com/wp-content/uploads/2023/07/NHS-may-increase-the-cost-of-new-antibiotic-subscriptions.jpg)
NHS may increase the cost of new antibiotic subscriptions
SG Tylor
Proposals are underway to double the yearly subscription payments made by NHS England to developers of innovative antibiotics from £10 ...
![Future NHS Award goes to an AI-based tool for heart disease](https://pharmtales.com/wp-content/uploads/2023/07/Future-NHS-Award-goes-to-an-AI-based-tool-for-heart-disease.jpg)
Future NHS Award goes to an AI-based tool for heart disease
SG Tylor
A digital tool created by NHS researchers to expedite the diagnosis of heart disease has been honored with the Future ...
![BMS' Sotyktu is approved for psoriasis usage by the NHS | Pharmtales](https://pharmtales.com/wp-content/uploads/2023/07/BMS-Sotyktu-is-approved-for-psoriasis-usage-by-the-NHS.jpg)
BMS’ Sotyktu is approved for psoriasis usage by the NHS
SG Tylor
Source: Bristol-Myers Squibb Just weeks after receiving approval in the UK, Bristol-Myers Squibb’s novel oral therapy for psoriasis, SotyKtu, has ...